US4879236A
(en)
*
|
1984-05-16 |
1989-11-07 |
The Texas A&M University System |
Method for producing a recombinant baculovirus expression vector
|
JPS619288A
(ja)
*
|
1984-06-21 |
1986-01-16 |
Dai Ichi Seiyaku Co Ltd |
ペプチド類の製法
|
IL80529A0
(en)
*
|
1985-11-14 |
1987-02-27 |
Daiichi Seiyaku Co |
Method of producing peptides
|
KR950001993B1
(ko)
*
|
1985-12-18 |
1995-03-08 |
마이크로제네시스,인코포레이티드 |
B형 간염 표면항원의 제조방법
|
IL83003A
(en)
|
1986-07-01 |
1995-07-31 |
Genetics Inst |
Osteoinductive factors
|
US6150328A
(en)
|
1986-07-01 |
2000-11-21 |
Genetics Institute, Inc. |
BMP products
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
EP0260090A3
(en)
*
|
1986-09-08 |
1988-07-27 |
David H.L. Bishop |
Expression of hepatitis b viral antigens from recombinant baculovirus vectors
|
ZA876696B
(en)
*
|
1986-09-09 |
1988-05-25 |
Genetics Inst |
Method for producing a heterologous protein in insect cells
|
US5071748A
(en)
*
|
1986-09-09 |
1991-12-10 |
Genetics Institute, Inc. |
Mixed baculovirus compositions and uses thereof
|
US5041379A
(en)
*
|
1987-03-16 |
1991-08-20 |
American Biogenetic Science, Inc. |
Heliothis expression systems
|
US5024947A
(en)
*
|
1987-07-24 |
1991-06-18 |
Cetus Corporation |
Serum free media for the growth on insect cells and expression of products thereby
|
US5443964A
(en)
*
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
US5578468A
(en)
*
|
1987-08-10 |
1996-11-26 |
Duke University |
Site-specific RNA cleavage
|
GB8810808D0
(en)
*
|
1988-05-06 |
1988-06-08 |
Wellcome Found |
Vectors
|
JP2511494B2
(ja)
*
|
1988-05-12 |
1996-06-26 |
善治 松浦 |
日本脳炎ウイルス表面抗原蛋白質の製造法
|
JPH0221955A
(ja)
*
|
1988-07-07 |
1990-01-24 |
Nippon Steel Corp |
流体噴射ノズル
|
SE8802939D0
(sv)
*
|
1988-08-19 |
1988-08-19 |
Kabigen Ab |
A method for the production and isolation of a fusion protein in eukaryotic cells
|
US5811523A
(en)
|
1988-11-10 |
1998-09-22 |
Trinchieri; Giorgio |
Antibodies to natural killer stimulatory factor
|
AU4647889A
(en)
*
|
1988-11-18 |
1990-06-12 |
Cetus Corporation |
Insect signal peptide mediated secretion of recombinant proteins
|
US5244805A
(en)
*
|
1989-05-17 |
1993-09-14 |
University Of Georgia Research Foundation, Inc. |
Baculovirus expression vectors
|
EP0612348B1
(en)
|
1991-11-04 |
2003-04-23 |
Genetics Institute, LLC |
Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
|
ATE258984T1
(de)
|
1993-05-12 |
2004-02-15 |
Inst Genetics Llc |
Bmp-11 zusammensetzungen
|
US6291206B1
(en)
|
1993-09-17 |
2001-09-18 |
Genetics Institute, Inc. |
BMP receptor proteins
|
US6027919A
(en)
|
1993-12-07 |
2000-02-22 |
Genetics Institute, Inc. |
BMP-12 and BMP-13 proteins and DNA encoding them
|
DE69434651T2
(de)
|
1993-12-07 |
2007-03-08 |
Genetics Institute, Inc., Cambridge |
Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
|
AU1377395A
(en)
|
1993-12-23 |
1995-07-10 |
University Technologies International Inc. |
Methods of expressing proteins in insect cells and methods of killing insects
|
US5629167A
(en)
|
1994-04-19 |
1997-05-13 |
Biocine S.P.A. |
Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6165748A
(en)
|
1997-07-11 |
2000-12-26 |
Genetics Institute, Inc. |
Frazzled nucleotide sequences and expression products
|
ATE505478T1
(de)
|
1997-08-27 |
2011-04-15 |
Novartis Vaccines & Diagnostic |
Molekular-mimetika von meningokokkalen b epitopen
|
WO1999024578A2
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
WO1999036544A2
(en)
|
1998-01-14 |
1999-07-22 |
Chiron S.P.A. |
Neisseria meningitidis antigens
|
GB9808932D0
(en)
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
ES2537575T3
(es)
|
1998-05-01 |
2015-06-09 |
Novartis Ag |
Antígenos y composiciones de neisseria meningitidis
|
WO2001031019A2
(en)
|
1999-10-29 |
2001-05-03 |
Chiron Spa |
Neisserial antigenic peptides
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
ATE408695T1
(de)
|
1998-12-16 |
2008-10-15 |
Novartis Vaccines & Diagnostic |
Menschliche cyclin-abhängige kinase (hpnqalre)
|
US6727224B1
(en)
|
1999-02-01 |
2004-04-27 |
Genetics Institute, Llc. |
Methods and compositions for healing and repair of articular cartilage
|
DK1228217T3
(da)
|
1999-04-30 |
2013-02-25 |
Novartis Vaccines & Diagnostic |
Konserverede neisseria-antigener
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
EP2308974A3
(en)
|
1999-10-14 |
2011-08-10 |
Clontech Laboratories Inc. |
Anthozoa derived chromo/fluoroproteins and methods for using the same
|
EP2286847A1
(en)
|
1999-10-15 |
2011-02-23 |
Genetics Institute, LLC |
Formulations of hyaluronic acid for delivery of osteogenic proteins
|
AU2001229367A1
(en)
|
2000-01-10 |
2001-07-24 |
Chiron Corporation |
Genes differentially expressed in breast cancer
|
EP1897555B1
(en)
|
2000-01-17 |
2014-07-16 |
Novartis Vaccines and Diagnostics S.r.l. |
Supplemented OMV vaccine against meningococcus
|
US6689599B1
(en)
|
2000-10-20 |
2004-02-10 |
Genetics Institute, Llc |
Aggrecanase molecules
|
MX357775B
(es)
|
2000-10-27 |
2018-07-20 |
J Craig Venter Inst Inc |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
ES2305246T3
(es)
|
2001-06-01 |
2008-11-01 |
Wyeth |
Composiciones para la administracion sistemica de secuencias que codifican proteinas oseas morfogeneticas.
|
TWI267378B
(en)
|
2001-06-08 |
2006-12-01 |
Wyeth Corp |
Calcium phosphate delivery vehicles for osteoinductive proteins
|
AU2002319703A1
(en)
|
2001-07-27 |
2003-02-17 |
Wyeth |
Aggrecanase molecules
|
CA2469620A1
(en)
|
2001-12-12 |
2003-06-19 |
Chiron Srl. |
Immunisation against chlamydia trachomatis
|
CA2467383C
(en)
|
2001-12-19 |
2012-08-28 |
The University Of Chicago |
Rapidly maturing fluorescent proteins and methods for using the same
|
WO2003064622A2
(en)
|
2002-01-31 |
2003-08-07 |
Wyeth |
Aggrecanase molecules
|
CA2475329A1
(en)
|
2002-02-05 |
2003-08-14 |
Katy E. Georgiadis |
Truncated aggrecanase molecules
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
CA2485695A1
(en)
|
2002-05-24 |
2003-12-04 |
Fred W. Wagner |
Method for universal enzymatic production of bioactive peptides
|
CA2485703A1
(en)
|
2002-05-24 |
2003-12-04 |
Fred W. Wagner |
Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
|
WO2004046177A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
AU2004272072B2
(en)
|
2003-09-12 |
2010-07-08 |
Etex Corporation |
Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
|
PL1704234T3
(pl)
|
2003-11-21 |
2012-06-29 |
Nps Pharma Inc |
Wytwarzanie glukagonopodobnego peptydu 2 i analogów
|
MXPA06008496A
(es)
|
2004-02-02 |
2007-01-30 |
Ambrx Inc |
Polipeptidos de interferon humano modificados y sus usos.
|
JP4792390B2
(ja)
|
2004-03-29 |
2011-10-12 |
株式会社ガルファーマ |
新規ガレクチン9改変体タンパク質及びその用途
|
US7250298B2
(en)
|
2004-04-07 |
2007-07-31 |
The University Of Chicago |
Monomeric red fluorescent proteins
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
CA2569381A1
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
KR20070090023A
(ko)
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
변형 인간 성장 호르몬
|
EP1828224B1
(en)
|
2004-12-22 |
2016-04-06 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
CA2602175C
(en)
|
2005-03-21 |
2012-11-27 |
Applera Corporation |
Alpha ketoamide compounds as cysteine protease inhibitors
|
AU2006247591B2
(en)
|
2005-05-12 |
2011-12-15 |
Zymogenetics, Inc. |
Compositions and methods for modulating immune responses
|
US7749704B2
(en)
|
2005-11-01 |
2010-07-06 |
Mayo Foundation For Medical Education And Research |
Promoter polymorphisms of the BLyS gene and use in diagnostic methods
|
CA2626522A1
(en)
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
EP2054431B1
(en)
|
2006-06-09 |
2011-08-31 |
Novartis AG |
Conformers of bacterial adhesins
|
EP2615108B1
(en)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and thier uses
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
KR20160121601A
(ko)
|
2007-03-30 |
2016-10-19 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
KR101662622B1
(ko)
|
2007-10-04 |
2016-10-05 |
지모제넥틱스, 인코포레이티드 |
B7 패밀리 구성원 zB7H6 및 관련된 조성물 및 방법
|
WO2009059305A2
(en)
|
2007-11-01 |
2009-05-07 |
The University Of Chicago |
Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
|
EP2217265B1
(en)
|
2007-11-20 |
2017-05-10 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
US8003325B2
(en)
|
2007-11-30 |
2011-08-23 |
Mayo Foundation For Medical Education And Research |
Polymorphisms of the BLyS gene and use in diagnostic methods
|
EP2247743B1
(en)
|
2008-02-08 |
2016-04-06 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
ES2963062T3
(es)
|
2008-07-23 |
2024-03-25 |
Ambrx Inc |
Polipéptidos G-CSF bovinos modificados y sus usos
|
NZ592249A
(en)
|
2008-09-26 |
2013-03-28 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
KR101647164B1
(ko)
|
2008-09-26 |
2016-08-09 |
암브룩스, 인코포레이티드 |
변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
|
EP2292781A1
(en)
|
2009-08-17 |
2011-03-09 |
Genethon |
Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
|
EP2333074A1
(en)
|
2009-12-14 |
2011-06-15 |
Robert Steinfeld |
Substances and methods for the treatment of lysosmal storage diseases
|
PE20121799A1
(es)
|
2009-12-21 |
2013-01-02 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos
|
JP2013515080A
(ja)
|
2009-12-21 |
2013-05-02 |
アンブルックス,インコーポレイテッド |
修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
RS59193B1
(sr)
|
2010-08-17 |
2019-10-31 |
Ambrx Inc |
Modifikovani polipeptidi relaksina i njihova primena
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
US10480010B2
(en)
|
2011-07-27 |
2019-11-19 |
Genethon |
Baculovirus expression systems
|
KR102484396B1
(ko)
|
2013-09-12 |
2023-01-04 |
바이오마린 파머수티컬 인크. |
아데노-관련된 바이러스 인자 viii 벡터
|
EP3209316A2
(en)
|
2014-10-24 |
2017-08-30 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
KR102805910B1
(ko)
|
2015-09-24 |
2025-05-13 |
바이오마린 파머수티컬 인크. |
아데노-관련 바이러스 인자 viii 벡터, 연합된 바이러스 입자 및 이를 포함하는 치료학적 제형
|
RU2761264C2
(ru)
|
2015-11-12 |
2021-12-06 |
Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал |
Способы лечения мышечной дистрофии
|
SG11201811603WA
(en)
|
2016-07-26 |
2019-02-27 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
SG10201912034UA
(en)
|
2017-02-08 |
2020-02-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
WO2019067982A2
(en)
|
2017-09-29 |
2019-04-04 |
Massachusetts Eye And Ear Infirmary |
PRODUCTION OF ADENO-ASSOCIATED VIRUSES IN INSECT CELLS
|
WO2019152474A1
(en)
|
2018-01-31 |
2019-08-08 |
Research Institute At Nationwide Children's Hospital |
Gene therapy for limb-girdle muscular dystrophy type 2c
|
CN113164762A
(zh)
|
2018-05-09 |
2021-07-23 |
生物马林药物股份有限公司 |
苯丙酮尿症的治疗方法
|
TW202016298A
(zh)
|
2018-05-14 |
2020-05-01 |
美商拜奧馬林製藥公司 |
Aav 載體於幼年受試者中之穩定表現
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
TWI854984B
(zh)
|
2018-06-29 |
2024-09-11 |
美國全美兒童醫院之研究學會 |
用於治療肢帶型肌營養不良症2a之重組腺相關病毒產品與方法
|
AU2020229340A1
(en)
|
2019-02-26 |
2021-09-16 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy
|
TW202104592A
(zh)
|
2019-05-14 |
2021-02-01 |
美商拜奧馬林製藥公司 |
重複投予基因療法載體之方法
|
MX2022002132A
(es)
|
2019-08-21 |
2022-05-18 |
Res Inst Nationwide Childrens Hospital |
Administracion de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular.
|
CA3153782A1
(en)
|
2019-09-27 |
2022-03-08 |
Biomarin Pharmaceutical Inc. |
Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies
|
US20230340078A1
(en)
|
2019-11-14 |
2023-10-26 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with liver-specific gene therapy vectors
|
US20230075854A1
(en)
|
2020-02-10 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Virus-free cell cultures
|
WO2021183895A1
(en)
|
2020-03-13 |
2021-09-16 |
Biomarin Pharmaceutical Inc. |
Treatment of fabry disease with aav gene therapy vectors
|
AR122409A1
(es)
|
2020-04-03 |
2022-09-07 |
Biomarin Pharm Inc |
Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
CA3196778A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical, Inc. |
Process for enriching adeno-associated virus
|
US20240408240A1
(en)
|
2021-10-01 |
2024-12-12 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
|
US12285497B2
(en)
|
2021-10-15 |
2025-04-29 |
Research Institute At Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
EP4590839A1
(en)
|
2022-09-22 |
2025-07-30 |
Dinaqor AG |
Treatment of cardiomyopathy with aav gene therapy vectors
|
TW202444398A
(zh)
|
2023-01-09 |
2024-11-16 |
美商拜奧馬林製藥公司 |
表觀遺傳修飾劑改善aav基因療法之耐久性
|
WO2024238591A2
(en)
|
2023-05-15 |
2024-11-21 |
Biomarin Pharmaceutical Inc. |
Methods of treating anti-aav seropositive hemophilia patients
|